Skip to main content
Premium Trial:

Request an Annual Quote

Zoetis to Incorporate Eureka Genotyping Tech into Animal Genetics Products

NEW YORK (GenomeWeb) – Eureka Genomics today announced an agreement with animal health firm Zoetis for use of Eureka's next-generation genotyping technology in its products.

Zoetis will use Eureka's technology — which combines high-throughput genetic sequencing and proprietary DNA processing and computing solutions — for its cattle and sheep genetics business. As part of the deal, Florham Park, NJ-based Zoetis has obtained the rights to incorporate the technology into existing and new products. It also has options to distribute products already developed by Eureka.

Eureka is exclusively providing Zoetis certain next-generation genotyping services and the firms will partner on new product development, Eureka said. While distribution options are being reviewed, Eureka will continue working with existing customers, the Hercules, Calif.-based firm added.

Zoetis Global Head of Genetics Jon Lowe said in a statement that Eureka's next-generation genotyping service will "replace some of our current genotyping platforms and provide opportunities for the development of new products and services."

Financial and other terms of the deal were not disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.